SFM
CAPR icon

Sphera Funds Management’s Capricor Therapeutics CAPR Stock Holding History

Sphera Funds Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-61,698
Closed -$938K – 114
2024
Q3 		$938K Buy
+61,698
New +$305K 0.15% 100

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sphera Funds Management's CAPR Position: Q4 2024 in Review

Sphera Funds Management sold out of Capricor Therapeutics (CAPR) in Q4 2024, closing a stake of 61,698 shares — an estimated $938K sold.

Sphera Funds Management first reported a position in CAPR in Q3 2024 and held it in 1 quarter. The position peaked at $938K in Q3 2024. 108 funds tracked by Wall St. Rank hold CAPR as of Q4 2024.

  • Sphera Funds Management reported no remaining Capricor Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sphera Funds Management sold 61,698 Capricor Therapeutics shares in Q4 2024, an estimated $938K.
  • Sphera Funds Management first reported a position in Capricor Therapeutics in Q3 2024 and held it in 1 quarter.
  • Sphera Funds Management's Capricor Therapeutics position peaked at $938K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2024.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.